For investors looking to join fundamental growth with well-timed technical entries, a layered screening method can be effective. One such technique involves selecting for stocks that show solid earnings momentum, are in a good technical uptrend, and are now pausing in a formation that indicates a possible next move higher. This method tries to find companies with improving business fundamentals just as their share prices are ready for their next advance. A screen that calls for a high ChartMill High Growth Momentum Rating (HGM), a good Technical Rating (TA), and a high Setup Quality Rating is made to find exactly these situations.
One stock that recently appeared from such a search is Kiniksa Pharmaceuticals International Plc (NASDAQ:KNSA), a commercial-stage biopharmaceutical company.
Fundamental Growth Momentum
Kiniksa’s fundamental profile makes a strong case for growth-oriented investors, which is seen in its HGM Rating of 7. The company is showing good momentum across important financial measures, a central idea of growth investment methods.
- Strong Earnings Growth: The company’s earnings per share (EPS) growth is especially notable. Year-over-year EPS growth for the trailing twelve months is over 221%. More notably, recent quarterly comparisons show faster growth, with the last quarter’s EPS growing 242% compared to the same period a year earlier, after a 228% increase the quarter before that.
- Solid and Increasing Revenue: Top-line growth is equally solid, with annual revenue growth above 60%. Quarterly sales growth has been steadily good, with the most recent quarter up nearly 65% year-over-year.
- Good Cash Generation: The company’s change is further shown by its free cash flow, which has grown by over 436% in the past year, showing the business model is advancing and producing notable operational cash.
- Positive Surprises and Revisions: Kiniksa has exceeded consensus EPS estimates in two of the last four quarters, with an average beat of over 23%. Also, analysts have been raising their revenue estimates for the next year by more than 4% over the last three months, indicating increasing confidence in the company’s commercial path.
This mix of high growth rates, faster growth, and positive analyst opinion forms the base of the high growth momentum view for KNSA.
Technical Strength and Trend
While good fundamentals are important, the timing of an entry is often guided by the stock’s technical state. According to the detailed ChartMill Technical Report, Kiniksa gets a very good 9 out of 10 on its Technical Rating. This score measures the overall condition and trend of the stock.
- Long-Term Uptrend Holding: The long-term trend is labeled as positive, with the stock trading well above its key moving averages (50-day, 100-day, and 200-day SMAs), which are all in rising arrangements.
- Market Leadership: The stock shows relative strength leadership, doing better than 93% of all stocks in the market over the past year and 80% of its peers in the Biotechnology industry. It is trading in the upper part of its 52-week range, in line with the broader S&P 500.
- Pause Within Uptrend: The short-term trend is now neutral, which, within the setting of a good long-term uptrend, often signals a healthy pause or rest. This is exactly what the Setup Quality Rating tries to find.
The Setup and Possible Entry
The present technical pause is where the chance for a clear entry appears. Kiniksa’s Setup Rating of 7 signals a time of lower volatility and price consolidation, which can come before a new move higher. The technical report notes that prices have been consolidating recently within a one-month range, forming a base.
- Clear Support and Resistance: The analysis finds a clear resistance area just above the present price at $47.78, made by a mix of trendlines. A clear move above this level could signal the restart of the uptrend.
- Defined Risk Management: Below the present price, a support area between $45.14 and $45.81 gives a logical place for a stop-loss order, offering a measurable risk point. The report automatically proposes a possible trade setup with an entry just above resistance at $47.79 and an exit stop below support at $45.13.
- Institutional Interest: A positive technical point is that the report sees recent activity from large players, as measured by the Effective Volume indicator, which can be a supporting sign during a consolidation period.
Conclusion
Kiniksa Pharmaceuticals presents a case where solid fundamental momentum meets a positive technical setup. For investors using a high-growth momentum method, the company’s strong earnings and sales growth, cash flow generation, and positive estimate revisions meet the fundamental needs. At the same time, the good long-term technical trend, market-leading relative strength, and present consolidation formation offering a clear breakout level and stop-loss area address the important "when to buy" question. This match is what specific screens aim to find.
Interested in locating other high-growth momentum stocks with well-timed technical setups? You can run the screen yourself using the High Growth Momentum Breakout Setups Screen on ChartMill to find other possible candidates that fit these specific conditions.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. The analysis presented is based on data and tools provided by ChartMill and should not be the sole basis for any investment decision. Investors should conduct their own due diligence and consider their individual financial circumstances and risk tolerance before trading. The suggested trade setup is automatically generated and for illustrative purposes only, actual trading involves risk, including the possible loss of principal.